358例新确证HIV感染者首次CD4+T淋巴细胞和病毒载量检测及相关性分析

目的 探讨 CD4⁺T 淋巴细胞和病毒载量检测结果的相关性,了解感染者基线免疫学和病毒学状况,为平顶山市艾滋病防治和监测工作提供基础数据。 方法 采用流式细胞仪和病毒载量分析仪检测 2018 年—2021 年平顶山市358 例新确证 HIV 感染者的同期首次外周血 CD4⁺T 淋巴细胞和病毒载量,SPSS 20. 0 软件分析数据。 结果 358 例新确证 HIV 感染者中首次 CD4⁺T 淋巴细胞计数结果在 10 个/ μl ～ 1 430 个/ μl,均值为(276. 31 ± 191. 64)个/ μl,不同性别、婚姻状况、文化程度、感染途径的 CD4⁺T 淋巴细胞检测结果比较,差异均无统计学意义(P> 0. 05),不同年龄组、职业、样本来源的 CD4⁺T 淋巴细胞均值差异有统计学意义;358 例病毒载量检测结果中,30 例低于试剂盒检测下限( < 20 拷贝/ ml),定量检测出数值 328 例,主要分布在 10⁴拷贝/ ml ～ 1...     

新报告HIV感染者/AIDS基线病毒载量水平与CD4+/CD8+比值分析

目的 分析江西省2015—2019年新报告艾滋病病毒(HIV)感染者/艾滋病(AIDS)病人(简称HIV感染者/AIDS)的基线病毒载量水平与其细胞免疫水平之间的关系。方法 对2015—2019年在江西省疾病预防控制中心确证的HIV感染者/AIDS进行基线CD4⁺T淋巴细胞、CD8⁺T淋巴细胞和病毒载量检测,用SPSS软件对数据进行相关性分析和二元logistic回归分析。结果 新报告HIV感染者/AIDS 513例,CD4⁺T淋巴细胞计数中位数为209个/μl,CD4⁺/CD8⁺比值中位数为0.233,病毒载量中位数为5.06 log₁₀ 拷贝/ml。病毒载量水平与CD4⁺T淋巴细胞、CD4⁺/CD8⁺比值总体呈显著负相关; CD4⁺/CD8⁺比值<0.20 的HIV感染者/AIDS其病毒载量≥10⁵拷贝/ml的风险为CD4⁺/CD8⁺比值≥0.20的3.775倍。结论 江西省新报告HIV感染者/AIDS中高病毒载量比例高,中位病毒载量高,CD4⁺/CD8⁺比值<0.2是高病毒载量的预测因素。应进一步加强扩大检测人群和比例,尽早发现感染者并进行抗病毒治疗,提高患者期望寿命。     

HIV感染者CD4/CD8细胞与病毒载量的关系

目的　探讨HIV感染者体内CD4细胞数与病毒载量的关系。方法　对 84人的 2 0 7次血样进行病毒载量的测定 ,对 194人的 491次血样进行CD4/CD8细胞数的检测。CD4/CD8细胞计数采用流式细胞仪的绝对计数法进行检测 ,使用核酸序列测试 (NASBA)方法检测病毒载量。对其中一部分人进行随访 ,采集血样并检测相应指标。结果　HIV感染者体内的CD4细胞数与病毒载量的Log值呈负相关 (r =-0 576,P <0 0 1) ,CD4/CD8比值与病毒载量的Log值呈负相关 (r =-0 544,P <0 0 1)。CD4细胞数较低的感染者 ,CD8细胞数也较低。在HIV感染者体内 ,随着病毒载量的升高 ,CD4细胞数呈下降趋势。结论　病毒载量与CD4有明显的相关关系 ,当病毒载量较低时 ,使用CD4细胞数可以粗略估计血浆中病毒载量的高低。CD4/CD8比值与病毒载量的Log值呈现负相关。当病毒载量较高时 ,HIV感染者体内病毒载量与CD4细胞数的变化趋势相反 ,但不完全同步     

2016年南京市新确证HIV感染男男性行为者首次CD4、CD8淋巴细胞计数分析

了解南京市HIV阳性男男性行为者(MSM)首次CD4淋巴细胞及CD4/CD8水平。方法抽取2016年新确证的MSM HIV感染者全血,采用罗氏COBAS HIV-1行HIV RNA检测,采用流式细胞仪进行CD4、CD8淋巴细胞计数。结果283例MSM HIV感染者中,79.5%的HIV病毒载量≥103copies/mL,CD4淋巴细胞计数平均为(370±223.7)/mm~3,中位数为352/mm~3(IQR220~506/mm~3),22.6%的CD4淋巴细胞计数<200/mm~3,85.5%的样本CD4/CD8<0.6。不同病毒载量人群CD4淋巴细胞计数、CD4/CD8比值分布差异均有统计学意义(P<0.05)。结论南京市新发现的MSM HIV感染者呈现出的病毒载量较高,CD4淋巴细胞计数、CD4/CD8比值均较低的特点。     

HIV/AIDS患者病毒载量与CD4细胞数相关性研究

[目的]探讨HIV感染者体内CD4细胞数与病毒载量的相关性。[方法]通过RT-PCR方法和流式细胞仪(FACSCOUNT)绝对计数法检测176名HIV感染者/艾滋病病人的HIV病毒载量和CD4细胞数,并进行随访。[结果]通过相关性分析显示病毒载量与CD4细胞数之间存在负相关关系(相关系数r=-0.547,P﹤0.05)。83例病人的病毒载量随访结果显示没有检测到病毒,大部分感染者CD4细胞数大于200个/mm3,HAART对抑制体内病毒复制起到了有效的作用,增强了机体免疫力。[结论]HIV感染者体内的CD4细胞数与病毒载量的值呈负相关性(相关系数r=-0.547,P﹤0.05),在HIV感染者/艾滋病病人体内,随着病毒载量的上升,CD4细胞数呈现不同程度的下降趋势。     

不同时期HIV病毒载量与T细胞亚群之间关系的研究

目的研究不同时期HIV感染者血液中的病毒载量与T细胞亚群之间关系。方法选取62例HIV感染者和10例健康人为对照,感染者依据病程时期分为3组,采用荧光PCR检测技术测定血液中HIV病毒载量和流式细胞仪计数外周血中CD3~+、CD4~+、CD8~+淋巴细胞。通过分析得出之间关系。结果处于不同疾病阶段的(无症状感染者、有症状感染者和AIDS病人)的血浆病毒载量不同,组间有统计学意义(P<0.05),艾滋病组的病毒载量最高为4.32×106,远高于其他组,3组中的CD4~+细胞、CD4~+/CD8~+比值下降且明显低于正常人群(P<0.05)具有统计学意义。各因素的相关性分析显示:HIV病毒载量与CD3~+、CD4~+细胞及CD4~+/CD8~+比值之间有高度直线负相关关系,与CD8+细胞无直接相关性。结论不同时期的HIV感染者其病毒载量水平、免疫学状况有明显不同。当HIV病毒载量升高时,CD4~+细胞、CD4~+/CD8~+比值下降,提示疾病处于进展中。因此,检测这些指标变化可为HIV的临床分期、判断预后和治疗提供依据。     

HIV感染者免疫状态与病毒载量的关系

目的了解HIV感染者体内CD3、CD4、CD8细胞计数与病毒载量间的关系。方法对无锡市2014—2015年199例HIV确证阳性者开展CD3、CD4、CD8淋巴细胞计数检测和病毒载量测定,细胞计数采用流式细胞仪的绝对计数法,病毒载量采用荧光定量PCR法。结果 199例HIV确证阳性者细胞计数范围,CD3为277~5 215/μL,CD4为12~1 183/μL,CD8为141~4 176/μL,196份(占98.49%)的标本CD4/CD8比值1。CD3、CD4细胞计数与HIV病毒载量(对数转换)均呈负相关,相关系数分别为-0.238(P=0.038)、-0.350(P0.01)。CD8细胞计数、CD4/CD8细胞比值与HIV病毒载量(对数转换)无统计学上的相关关系。结论 HIV病毒载量与CD3、CD4淋巴细胞含量有一定的相关性。     

HIV感染患者CD_4~+T淋巴细胞数与病毒载量分析

目的通过了解新发现艾滋病病毒(HIV)感染者的免疫状况和HIV在体内复制水平,以便预测疾病进展情况。方法分别用流式细胞仪和NASBA方法检测190例新发现HIV感染者CD4+T淋巴细胞计数和病毒载量。结果新发现HIV感染者CD4+T淋巴细胞计数均值为268.31/mm3,标准差为223.45/mm3;其中CD4+T淋巴细胞计数<50/mm3 35例,占18.4%;50²00/mm3 40例,占21.1%;200200/mm3 40例,占21.1%;200³50/mm3 64例,占33.7%;>350/mm351例,占26.8%;新发现HIV感染者病毒载量为1.95350/mm3 64例,占33.7%;>350/mm351例,占26.8%;新发现HIV感染者病毒载量为1.95⁷.0log/ml,均值为4.55log/ml,标准差为0.90log/ml;其中病毒载量<3log/ml 9例,占4.7%;37.0log/ml,均值为4.55log/ml,标准差为0.90log/ml;其中病毒载量<3log/ml 9例,占4.7%;3⁴log/ml 39例,占20.5%;44log/ml 39例,占20.5%;4⁵log/ml 81例,占42.6%;>5log/ml 61例,占32.1%;随着CD4+T淋巴细胞数的升高,病毒载量呈降低趋势,通过相关回归分析,CD4+T淋巴细胞数与病毒载量之间存在明显的负相关(r=-0.374,P<0.01)。结论新发现HIV感染者免疫机能差,病毒复制水平高,大部分感染者进入发病高峰期,需要抗病毒治疗。     

性传播感染的HIV/AIDS抗病毒治疗CD4~+T淋巴细胞计数和HIV病毒载量结果分析

目的探讨性传播感染的人类免疫缺陷病毒(感染者)/艾滋病(患者)(HIV/AIDS)抗病毒治疗CD4+T淋巴细胞计数和HIV载量变化。方法选取2012年1月—2015年1月凉山彝族自治州第一人民医院就诊的通过性传播途径感染HIV/AIDS 160例,分别使用流式细胞仪和依赖核酸序列的扩增技术(NASBA)方法检测抗病毒治疗前及6个月后CD4+T淋巴细胞计数和病毒载量。结果 1治疗前患者CD4+T淋巴细胞计数为(262.7±21.8)个/μl,治疗后为(316.4±208.9)个/μl,治疗前患者病毒载量为(4.55±0.91)log/ml,治疗后病毒载量为(1.48±0.47)log/ml,治疗前后差异有统计学意义(P0.01);2不同性别、年龄分组研究对象CD4+T淋巴细胞计数和病毒载量治疗前后均有不同;3CD4+T淋巴细胞计数与病毒载量之间呈显著负相关(r=-0.486,P0.01)。结论性传播感染HIV/AIDS抗病毒治疗后CD4+T淋巴细胞计数上升,病毒载量下降,应结合指标变化制定合理方案开展抗病毒治疗。     

HIV/AIDS患者外周血T淋巴细胞亚群与血清HIV RNA病毒载量的相关性研究

目的探讨HIV/AIDS患者外周血T淋巴细胞亚群与血清HIV RNA病毒载量的相关性。方法选取2017年1月-2018年6月在杭州市西溪医院就诊的艾滋病感染者40例以及AIDS患者32例,在未经抗病毒治疗前采用RT-PCR技术检测血清中HIV RNA载量,流式细胞仪进行T淋巴细胞亚群检测计数CD4~+、CD8~+T淋巴细胞。结果 HIV感染组血清中HIVRNA检出率为75%(30/40),平均载量为(3.08±1.49)lgCopies/ml,CD4~+平均计数为(235.24±79.53)个/μl, CD4~+/CD8~+平均值为0.38±0.17;AIDS患者组血浆中HIV RNA检出率为87.5%(28/32),平均载量为(4.57±2.25)lgCopies/ml,CD4~+平均计数为(135.24±55.20)个/μl, CD4~+/CD8~+平均值为0.23±0.14,两组间比较差异有统计学意义(P0.05);血清HIV RNA载量与CD4~+计数呈负相关(r=-0.742,r=-0.561,P0.05)。结论 AIDS患者较HIV感染者HIV RNA平均载量高,CD4~+平均含量低;而CD4~+计数、CD4~+/CD8~+比值与HIVRNA载量呈负相关,病毒载量越高,CD4~+计数、CD4~+/CD8~+比值越低。     

HIV病毒载量定量测定方法的比较研究

[目的 ]　比较不同检测方法对人类免疫缺陷病毒 (HIV )病毒载量间的一致性 ,供临床应用选择方法时参考。[方法 ]　在上海地区对HIV感染者和艾滋病 (AIDS)病人采集 91份标本 ,每份标本同时用bDNA法和NASBA法测定 ,比较两者检出率、相关性和不一致性。 [结果 ]　HIV病毒载量检出率均在 80 % ,且无样本错位 ;两种方法检测的HIV病毒载量Log值呈高度线性相关 ,同时发现 7例病人两种方法测得的病毒载量存在明显差异。 [结论 ]　bDNA法和NASBA法检测HIV病毒载量具有高度一致性 ,在实际工作中可任意选用 ,NASBA法在HIVRNA低浓度时敏感性更高 ,bDNA法则测得更广泛的亚型标本     

Using the HIV Surveillance System to Monitor the National HIV/AIDS Strategy

Objectives. To report on indicators of the National HIV/AIDS Strategy, we analyzed data collected through the national HIV surveillance system.Methods. We analyzed data from adults and adolescents aged 13 years or older diagnosed with HIV in 13 US jurisdictions that have laboratory reporting of CD4+ T-lymphocyte (CD4) and viral load (VL) test results and enter CD4 and VL test results into the national surveillance system.Results. Of 4899 people diagnosed in 2009, 81.7% had at least 1 CD4 or VL test performed within 3 months of diagnosis. A higher proportion of Whites (86.2%) than Blacks (78.4%) and Hispanics (82.6%) had a CD4 or VL test. Of 53 642 people diagnosed through 2008 and living with HIV at the end of 2009 who had a VL test, 69.4% had a most recent VL of 200 copies per milliliter or less. The proportion of people with suppressed VLs differed among Blacks (60.2%), Hispanics (70.3%), and Whites (77.4%) and among people aged 13 to 24 years (44.3%) compared with people aged 65 years or older (84.2%). Of men who have sex with men, 74.2% had a suppressed VL.Conclusions. The findings highlight disparities in access to and success of care.In 2010, the White House released the National HIV/AIDS Strategy, centered on reducing new HIV infections, increasing access to care and improving health outcomes for people living with HIV, and reducing HIV-related disparities.1 Specific targets to achieve by 2015 include increasing the proportion of newly diagnosed patients linked to clinical care within 3 months of diagnosis from 65% to 85% and increasing the proportion of HIV-diagnosed gay and bisexual men, Blacks, and Hispanics with undetectable viral loads (VLs) by 20%. HIV surveillance data can be used to monitor the nation’s progress toward the National HIV/AIDS Strategy goals to improve a timely link to care and increase the proportion of HIV-infected people who are virally suppressed.Successful medical treatment of a person with HIV and the prevention of new infections requires the identification of infection at an early stage of disease, timely linkage to clinical care, prompt initiation of combination antiretroviral therapy when indicated, regular care visits, and adherence to prescribed antiretroviral therapy regimens.2–5 Antiretroviral therapy reduces plasma and genital HIV-1 RNA levels and is associated with reduced probability of HIV transmission.6–9 Patients who adhere to therapy and engage in routine health care are more likely to achieve viral suppression than those who do not see their providers regularly.10 Because the quantity of HIV-1 RNA in plasma is correlated with the risk of HIV-1 transmission, people with suppressed viral loads are less infectious and therefore less likely to transmit HIV infection.7,9The US Department of Health and Human Services’ Panel on Antiretroviral Guidelines for Adults and Adolescents has recommended CD4+ T-lymphocyte count (CD4) and VL testing for new patients during the initial visit to guide the initiation of treatment.11 To monitor disease status and the response to treatment, VL testing is recommended every 3 to 4 months after HIV diagnosis, and CD4 monitoring should occur at least every 6 to 12 months among patients who are clinically stable.Data collected through the national HIV surveillance system can be used to monitor key outcomes of the national strategy; however, monitoring outcomes such as linkage to care and racial/ethnic disparities among people who are virally suppressed is particularly dependent on complete reporting of all HIV-related laboratory results, including CD4 and VL results, to surveillance. Although most HIV surveillance jurisdictions have regulations that require laboratories to report CD4 and VL results to health departments, not all areas have mandatory reporting of all levels of CD4 counts and percentages and detectable and undetectable VLs.12 We present findings from an analysis of data collected through the national HIV surveillance system to report on indicators outlined in the national strategy and factors associated with linkage to care and viral suppression.     

HIV/HCV共感染对HIV一1生物学特性影响的研究

目的研究有偿献血人群HIV／HCV共感染对HIV-1基因离散率、病毒载量、CD4 T淋巴细胞等生物学特性影响。方法扩增HIV-1 env基因C2～V3区,Clustal W和Phylip软件计算基因离散率,NASBA方法检测HIV-1病毒载量,采用Coulter公司的Epics XL流式细胞计数仪检测CD4 细胞数,用SPSS软件t检验分析HIV／HCV共感染对HIV-1生物学特性的影响。结果HCV共感染与非共感染人群的HIV-1平均基因离散率为7．95％、15．73％(P<0．001),平均病毒载量为4．61、4．45(P=0．522),平均CD4 T淋巴细胞数为308、251(P=0．161)。结论该有偿献血人群中HIV／HCV共感染对HIV-1基因离散率有影响,而对病毒载量、CD4 T淋巴细胞无影响。     

Quality of life in HIV subtype C infection among asymptomatic subjects and its association with CD4 counts and viral loads – a study from South India

Objective

To study the association between quality of life (QOL) domains and biological markers of disease progression of HIV infection, i.e. viral load (VL) and CD4 counts among asymptomatic subjects with HIV subtype C infection in South India.

Design

Quality of life was measured using the locally validated version of the WHOQOL HIV-BREF. The subjects were neurologically asymptomatic, non psychiatrically ill HIV infected men and women participating in a cohort study.

Results

The results indicated mixed findings, with some QOL dimensions being associated with high VLs and low CD4 counts while several others did not show any associations. Significant associations were seen between low CD4 counts and the psychological and social relationships domain, with lower mean scores in these domains being reported by subjects having CD4 counts <200 /mm. However, there were no significant differences between the CD4 subgroups for the domains related to physical health, level of independence, environment, and spirituality domains. Significant lower mean QOL scores were found in the highest VL subgroup compared to other groups for the following WHOQOL HIV-BREF domains: physical, psychological, level of independence, and environmental.

Conclusions

In this sample of HAART naïve asymptomatic HIV infected subjects, some QOL dimensions were associated with the biological markers of disease progression i.e. VL and CD4 counts, while several were not. The associations were significant only in the high VL and low CD4 groups.     

两种高效抗反转录病毒方案预防艾滋病母婴传播的效果

目的:了解两种高效抗反转录病毒(HAART)方案预防艾滋病母婴传播的效果,为进一步合理选择母婴阻断抗病毒治疗方案提供依据。方法:采用两种方案(齐多夫啶AZT+拉米夫啶3TC+克力芝LPV/r和齐多夫啶AZT+拉米夫啶3TC+施多宁/奈韦拉平EFV/NVP)预防艾滋病母婴传播,对入组病例在服药前、孕36周及产后3个月进行CD4+T淋巴细胞计数和血浆HIV病毒载量测定。结果:共入组72例孕产妇,所生73例婴儿除1例因新生儿窒息死亡外,其余72例经早期HIVDNA-PCR核酸检测,结果均为阴性;血浆病毒载量在孕36周时最低(P<0.001);CD4+T淋巴细胞水平从治疗前至产后3个月呈增高趋势(P<0.001);治疗前后的病毒载量及CD4+T淋巴细胞平均水平两组间均无统计学差异(P>0.05)。结论:两种HAART方案预防艾滋病母婴传播效果显著,在病毒抑制和提高CD4+T淋巴细胞计数上两方案效果一致。     

Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS cohort

Many studies have chronicled the "epidemiologic synergy" between human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2). HIV adversely affects the natural history of HSV-2 and results in more frequent and severe HSV-2 reactivation. Few longitudinal studies, however, have examined whether HSV-2 is associated with increased HIV plasma viral loads or decreased CD4 counts. The authors estimated the effect of HSV-2 seropositivity on HIV RNA viral load and on CD4 count over time among 777 HIV-seropositive US women not receiving suppressive HSV-2 therapy in the HIV Epidemiology Research Study (1993-2000). Linear mixed models were used to assess the effect of HSV-2 on log HIV viral load and CD4 count/mm(3) prior to widespread initiation of highly active antiretroviral therapy. Coinfection with HSV-2 was not associated with HIV RNA plasma viral loads during study follow-up. There was a statistically significant association between HSV-2 seropositivity and CD4 count over time, but this difference was small and counterintuitive at an increase of 8 cells/mm(3) (95% confidence interval: 2, 14) per year among HSV-2-seropositive women compared with HSV-2-seronegative women. These data do not support a clinically meaningful effect of baseline HSV-2 seropositivity on the trajectories of HIV plasma viral loads or CD4 counts.     

Associations between helminth infection and CD4+ T cell count,viral load and cytokine responses in HIV-1-infected Ugandan adults

It has been proposed that helminth infection may exacerbate HIV progression by promoting activation of 'type 2' immune responses. To examine this hypothesis, we investigated helminth infection in a cohort of HIV-1-seropositive adults in Entebbe, Uganda, during November 1999 to January 2000. Individuals with helminths were treated. At enroLlment, after 5 weeks and after 4 months, CD4+ and CD8+ T cell counts and viral load were measured. Cytokine responses (interferon [IFN]-gamma, interleukin [IL]-2, IL-4 and IL-5) to Schistosoma mansoni adult worm antigen (SWA), Mycobacterium tuberculosis culture filtrate proteins (CFPs) and phytohaemagglutinin (PHA) were measured in a whole blood assay. At baseline, CD4+ T cell counts and CD4+: CD8+ ratios were higher in individuals with helminths than in those without (median CD4+ T cell counts 467/microL and 268/microL, respectively, P = 0.005). Viral load was lower among those with helminths but this was not statistically significant. During follow-up, CD4+ T cell counts and cytokine responses to PHA fell among individuals without helminths. Among those treated for helminths, CD4+ counts remained stable. Viral loads showed a transient increase at 5 weeks, which was more marked among those treated for helminths, but the levels at 4 months were similar to baseline in both groups. Among those with schistosomiasis, IFN-gamma and IL-2 responses to CFP, and IL-2 and IL-4 responses to PHA declined but there was a sustained increase in cytokine responses to SWA following treatment. These data do not support the hypothesis that helminth infection exacerbates HIV infection. The possibility that chronic helminth infection may suppress HIV replication and that effects on HIV replication may vary during helminth infection and treatment should be considered.     

山东省艾滋病抗病毒治疗病毒学评价

[目的]评价山东省艾滋病抗病毒治疗病毒学效果。[方法]对山东省2012年6月30日前治疗满6个月的艾滋病病人,使用荧光实时定量PCR（NucliSensEasyQ）进行病毒载量检测,使用流式细胞学技术进行CD4＋T淋巴细胞计数。[结果]925例艾滋病病人中,826例病毒载量结果〈400cp／ml,病毒抑制率为89．30％;99例载量结果〉400cp／ml病人中,28例出现了病毒反弹,1例为持续性低水平病毒血症,CD4＋T淋巴细胞计数均值为312个／mm3,14例出现了机会性感染。54例采用二线抗病毒治疗方案的病人,病毒抑制率为81．48％。[结论]山东省艾滋病抗病毒治疗病毒抑制效果良好。     

HIV-1/HCV合并感染者中HCV基因亚型流行情况调查

目的 了解中国部分地区HIV-1和HCV合并感染人群中HCV基因亚型的流行、分布及其与HIV-1感染疾病进展的关系.方法 对186份获自河南、云南、新疆、吉林和辽宁省HIV-1/HCV合并感染人群标本(HCV病毒载量>1000 cop/ml),用反转录巢式聚合酶链反应方法扩增血浆HCV核心基因区并进行基因亚型分型,同时检测HIV-1和HCV载量以及CD4+T细胞计数.结果 (1)HCV不同基因亚型比例分别为1a(1.7%)、1b(39.9%)、2a(17.9%)、3a(10.4%)、3b(15.6%)、6a(1.2%)、6n(6.4%)和6型未鉴定亚型(7.5%).HCV 2a和1b主要流行于河南省既往有偿献血浆人员中;3a和3b亚型主要流行于新疆和云南静脉注射吸毒者(IDU)中;HCV6型主要流行于云南吸毒人员中.(2)1b亚型的HCVRNA水平显著高于非1b亚型,但在HIV-1载量和CD4+T细胞数方面差异无统计学意义.2a亚型的HIV-1 RNA和HCV RNA水平显著低于非2a亚型.结论 HIV-1/HCV合并感染人群中HCV基因亚型的流行和分布与流行地区和感染途径有关.新的HCV6型亚型病毒株已经在合并感染的IDU人群中流行.尚未发现HCV基因哑型与HIV感染疾病进展之间的关系.